Edward M. Md Kaye Sells 10,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Edward M. Md Kaye sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $410,000.00. Following the completion of the transaction, the director now owns 62,471 shares of the company’s stock, valued at $2,561,311. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) traded down 0.46% during midday trading on Friday, hitting $36.70. 1,272,093 shares of the stock were exchanged. The company’s 50 day moving average is $37.48 and its 200-day moving average is $33.08. Sarepta Therapeutics, Inc. has a 1-year low of $24.96 and a 1-year high of $63.73. The stock’s market cap is $2.36 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.46. The company had revenue of $35.01 million during the quarter, compared to the consensus estimate of $22.52 million. The business’s revenue was up 350000.0% on a year-over-year basis. During the same quarter last year, the firm earned ($1.19) EPS. On average, analysts expect that Sarepta Therapeutics, Inc. will post ($1.16) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was posted by BNB Daily and is owned by of BNB Daily. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/edward-m-md-kaye-sells-10000-shares-of-sarepta-therapeutics-inc-nasdaqsrpt-stock-updated-updated-updated.html.

SRPT has been the subject of several analyst reports. Piper Jaffray Companies set a $43.00 target price on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research report on Thursday, May 18th. Vetr cut shares of Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating and set a $36.86 target price for the company. in a research report on Monday, May 15th. SunTrust Banks, Inc. restated a “buy” rating and issued a $45.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, May 2nd. Cowen and Company reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a report on Friday, April 28th. Finally, Nomura reaffirmed a “buy” rating and set a $84.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, May 23rd. Eight analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $61.28.

A number of hedge funds have recently added to or reduced their stakes in the stock. Prentiss Smith & Co. Inc. boosted its stake in Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 3,166 shares during the period. Ameritas Investment Partners Inc. bought a new stake in Sarepta Therapeutics during the first quarter valued at $127,000. PNC Financial Services Group Inc. boosted its stake in Sarepta Therapeutics by 150.1% in the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 2,800 shares during the period. Cubist Systematic Strategies LLC boosted its stake in Sarepta Therapeutics by 116.4% in the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 2,474 shares during the period. Finally, Edge Wealth Management LLC bought a new stake in Sarepta Therapeutics during the second quarter valued at $175,000. Institutional investors and hedge funds own 63.11% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Insider Buying and Selling by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply